KLP Kapitalforvaltning AS Acquires 3,400 Shares of ADMA Biologics Inc $ADMA

KLP Kapitalforvaltning AS grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 7.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,700 shares of the biotechnology company’s stock after purchasing an additional 3,400 shares during the period. KLP Kapitalforvaltning AS’s holdings in ADMA Biologics were worth $905,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ADMA Biologics in the first quarter worth $35,000. SVB Wealth LLC bought a new stake in shares of ADMA Biologics in the first quarter worth $35,000. Toth Financial Advisory Corp grew its holdings in shares of ADMA Biologics by 1,081.6% in the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 2,293 shares during the period. Ameritas Advisory Services LLC bought a new stake in shares of ADMA Biologics in the second quarter worth $46,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,493 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of ADMA Biologics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and a consensus price target of $27.67.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $15.09 on Thursday. The company has a market capitalization of $3.60 billion, a PE ratio of 17.55 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The business’s fifty day moving average is $16.08 and its 200 day moving average is $18.45. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the previous year, the business earned $0.13 earnings per share. ADMA Biologics’s quarterly revenue was up 13.8% compared to the same quarter last year. Sell-side analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.